Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Identification and characterization of Nanobodies targeting the EphA4 receptor.

Schoonaert L, Rué L, Roucourt B, Timmers M, Little S, Chávez-Gutiérrez L, Dewilde M, Joyce P, Curnock A, Weber P, Haustraete J, Hassanzadeh-Ghassabeh G, De Strooper B, Van Den Bosch L, Van Damme P, Lemmens R, Robberecht W.

J Biol Chem. 2017 Jul 7;292(27):11452-11465. doi: 10.1074/jbc.M116.774141. Epub 2017 May 19.

2.

Epha3 acts as proangiogenic factor in multiple myeloma.

Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D.

Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100.

3.

Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization.

Mohanty S, Oruganty K, Kwon A, Byrne DP, Ferries S, Ruan Z, Hanold LE, Katiyar S, Kennedy EJ, Eyers PA, Kannan N.

PLoS Genet. 2016 Feb 29;12(2):e1005885. doi: 10.1371/journal.pgen.1005885. eCollection 2016 Feb. Erratum in: PLoS Genet. 2016 Aug;12(8):e1006265.

4.

Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3.

Zhao Y, Li H, Wu R, Li S, Wang P, Wang H, Wang J, Zhou J.

PLoS One. 2015 May 15;10(5):e0126726. doi: 10.1371/journal.pone.0126726. eCollection 2015.

5.

Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth.

To C, Farnsworth RH, Vail ME, Chheang C, Gargett CE, Murone C, Llerena C, Major AT, Scott AM, Janes PW, Lackmann M.

PLoS One. 2014 Nov 24;9(11):e112106. doi: 10.1371/journal.pone.0112106. eCollection 2014.

6.

Eph receptors and ephrins: therapeutic opportunities.

Barquilla A, Pasquale EB.

Annu Rev Pharmacol Toxicol. 2015;55:465-87. doi: 10.1146/annurev-pharmtox-011112-140226. Epub 2014 Oct 3. Review.

7.

Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.

Fauvel B, Yasri A.

MAbs. 2014 Jul-Aug;6(4):838-51. doi: 10.4161/mabs.29089. Epub 2014 May 14. Review.

8.

Tie2 and Eph receptor tyrosine kinase activation and signaling.

Barton WA, Dalton AC, Seegar TC, Himanen JP, Nikolov DB.

Cold Spring Harb Perspect Biol. 2014 Mar 1;6(3). pii: a009142. doi: 10.1101/cshperspect.a009142. Review.

9.

The composition of EphB2 clusters determines the strength in the cellular repulsion response.

Schaupp A, Sabet O, Dudanova I, Ponserre M, Bastiaens P, Klein R.

J Cell Biol. 2014 Feb 3;204(3):409-22. doi: 10.1083/jcb.201305037. Epub 2014 Jan 27.

10.

Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation.

Nikolov DB, Xu K, Himanen JP.

Biochim Biophys Acta. 2013 Oct;1834(10):2160-5. doi: 10.1016/j.bbapap.2013.04.020. Epub 2013 Apr 26. Review.

11.

Roles of EphB3/ephrin-B1 in feather morphogenesis.

Suksaweang S, Jiang TX, Roybal P, Chuong CM, Widelitz R.

Int J Dev Biol. 2012;56(9):719-28. doi: 10.1387/ijdb.120021rw.

12.

Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function.

Atapattu L, Saha N, Llerena C, Vail ME, Scott AM, Nikolov DB, Lackmann M, Janes PW.

J Cell Sci. 2012 Dec 15;125(Pt 24):6084-93. doi: 10.1242/jcs.112631. Epub 2012 Oct 29.

13.

Monoclonal antibodies in cancer therapy.

Scott AM, Allison JP, Wolchok JD.

Cancer Immun. 2012;12:14. Epub 2012 May 1. Review. No abstract available.

14.

Eph receptors and ephrins as targets for cancer therapy.

Xi HQ, Wu XS, Wei B, Chen L.

J Cell Mol Med. 2012 Dec;16(12):2894-909. doi: 10.1111/j.1582-4934.2012.01612.x. Review.

15.

Irradiation affects cellular properties and Eph receptor expression in human melanoma cells.

Mosch B, Pietzsch D, Pietzsch J.

Cell Adh Migr. 2012 Mar-Apr;6(2):113-25. doi: 10.4161/cam.20655. Epub 2012 Mar 1.

16.

Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors.

Janes PW, Griesshaber B, Atapattu L, Nievergall E, Hii LL, Mensinga A, Chheang C, Day BW, Boyd AW, Bastiaens PI, Jørgensen C, Pawson T, Lackmann M.

J Cell Biol. 2011 Dec 12;195(6):1033-45. doi: 10.1083/jcb.201104037. Epub 2011 Dec 5.

17.

EphA4 blockers promote axonal regeneration and functional recovery following spinal cord injury in mice.

Goldshmit Y, Spanevello MD, Tajouri S, Li L, Rogers F, Pearse M, Galea M, Bartlett PF, Boyd AW, Turnley AM.

PLoS One. 2011;6(9):e24636. doi: 10.1371/journal.pone.0024636. Epub 2011 Sep 13.

18.

Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma.

Valsesia A, Rimoldi D, Martinet D, Ibberson M, Benaglio P, Quadroni M, Waridel P, Gaillard M, Pidoux M, Rapin B, Rivolta C, Xenarios I, Simpson AJ, Antonarakis SE, Beckmann JS, Jongeneel CV, Iseli C, Stevenson BJ.

PLoS One. 2011 Apr 8;6(4):e18369. doi: 10.1371/journal.pone.0018369.

19.

Architecture of Eph receptor clusters.

Himanen JP, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L, Rajashankar KR, Mensinga A, Lackmann M, Nikolov DB, Dhe-Paganon S.

Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10860-5. doi: 10.1073/pnas.1004148107. Epub 2010 May 26.

20.

Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis.

Mosch B, Reissenweber B, Neuber C, Pietzsch J.

J Oncol. 2010;2010:135285. doi: 10.1155/2010/135285. Epub 2010 Mar 10.

Supplemental Content

Support Center